Synergistic Ultrasound Contrast Agent System

Publication ID: 24-11857646_0008_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Ultrasound Contrast Agent System,” Published Technical Disclosure No. 24-11857646_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857646_0008_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,646.

Summary of the Inventive Concept

A novel system integrating AI, IoT, blockchain, and new materials to create a more efficient, reliable, and quality-controlled ultrasound contrast agent manufacturing process, minimizing the impact of divalent metal cations.

Background and Problem Solved

The original patent disclosed improved methods for preparing phospholipid-based ultrasound contrast agents, but it had limitations in terms of formulation optimization, manufacturing process control, and quality verification. The new inventive concept addresses these limitations by incorporating advanced technologies to create a more robust and efficient system.

Detailed Description of the Inventive Concept

The synergistic system combines AI-assisted predictive modeling to optimize phospholipid formulations and minimize the impact of divalent metal cations. IoT sensors and machine learning algorithms are used for real-time monitoring of the manufacturing process to detect and prevent precipitation induced by divalent metal cations. A blockchain-based system tracks and verifies the composition and quality of the ultrasound contrast agents, ensuring transparency and trust in the supply chain. Additionally, novel materials with improved stability and resistance to divalent metal cations are fabricated using 3D printing techniques, and computer-implemented simulations predict the behavior of phospholipid-based ultrasound contrast agents in the presence of divalent metal cations.

Novelty and Inventive Step

The new claims introduce a synergistic combination of AI, IoT, blockchain, and new materials to create a more efficient, reliable, and quality-controlled ultrasound contrast agent manufacturing process, which is not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to address the limitations of the original patent.

Alternative Embodiments and Variations

Alternative embodiments may include the use of different AI algorithms, IoT sensor configurations, or blockchain platforms. Variations may include the application of the synergistic system to other types of contrast agents or medical imaging modalities.

Potential Commercial Applications and Market

The synergistic ultrasound contrast agent system has significant commercial potential in the medical imaging industry, particularly in the ultrasound market. The system's ability to improve manufacturing efficiency, quality control, and supply chain transparency can lead to increased adoption and revenue growth.

CPC Classifications

Section	Class	Group
A	A61	A61K49/223
A	A61	A61B8/481
A	A61	A61K49/226
A	A61	A61K49/227
C	C07	C07F9/09
C	C07	C07F9/106

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Medical imaging and pharmaceutical formulation technologies, specifically ultrasound contrast agent development, requiring expertise in lipid chemistry, materials science, sensor technologies, and computational modeling

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in chemical engineering, biomedical engineering, or pharmaceutical sciences, possessing knowledge of ultrasound imaging technologies, molecular formulation techniques, and emerging computational methods for materials optimization

Obviousness Rationale

A PHOSITA would recognize that integrating computational modeling, sensor technologies, and quality control systems into ultrasound contrast agent manufacturing represents a predictable application of known technological approaches to address the inherent challenges of phospholipid formulation stability. The proposed AI and IoT techniques directly address the source patent's core challenge of managing divalent metal cation interactions through systematic monitoring and predictive modeling. These technological extensions represent standard engineering problem-solving strategies applied to the specific domain of ultrasound contrast agent production.

Obvious Combinations & Variations

Source Patent Element

Phospholipid suspension method involving metal cation management

PTD Variation

AI-assisted predictive modeling to optimize phospholipid formulations

Obviousness Reasoning

Computational optimization of chemical formulations is a well-established technique in materials science, representing a predictable application of machine learning to existing chemical engineering challenges

Source Patent Element

Phospholipid blend formation techniques

PTD Variation

3D printing of novel materials with improved stability

Obviousness Reasoning

Advanced manufacturing techniques like 3D printing are routinely applied to materials development, offering a predictable method for creating specialized formulation structures

Source Patent Element

Metal cation concentration management

PTD Variation

IoT sensors for real-time manufacturing process monitoring

Obviousness Reasoning

Implementing sensor-based quality control represents a standard industrial engineering approach to process optimization, particularly in pharmaceutical manufacturing

Source Patent Element

Phospholipid suspension preparation method

PTD Variation

Blockchain-based composition tracking and verification

Obviousness Reasoning

Supply chain transparency and verification technologies are increasingly standard in regulated manufacturing environments, representing an obvious extension of existing quality control methodologies

Source Patent Element

Chemical formulation stability considerations

PTD Variation

Molecular dynamics simulations predicting phospholipid behavior

Obviousness Reasoning

Computational simulation of molecular interactions is a well-established technique in materials science, offering a predictable method for understanding complex chemical system behaviors

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857646 and the comprehensive technological extensions disclosed herein, a person of ordinary skill in the art would find the proposed ultrasound contrast agent manufacturing innovations to be obvious variations representing standard engineering problem-solving techniques applied to known pharmaceutical formulation challenges. The disclosed methods represent predictable combinations of computational modeling, sensor technologies, and advanced manufacturing approaches that would be readily conceived by a skilled practitioner seeking to optimize ultrasound contrast agent production processes.

Original Patent Information

Patent Number	US 11,857,646
Title	Methods for making ultrasound contrast agents
Assignee(s)	Lantheus Medical Imaging, Inc.